Home Authors Posts by Winway Health Desk

Winway Health Desk

2916 POSTS 0 COMMENTS

Gilead, Insitro in $250M machine learning partnership to develop NASH drugs

A large biotech company has made a deal with a smaller firm to incorporate a new weapon into its arsenal against nonalcoholic steatohepatitis: machine...

Booking beauty: Allergan’s new concierge platform Regi finds medical aesthetic and...

Regi—short for regimen—is Allergan’s first-ever digital booking platform for aesthetic treatments. That includes Allergan-branded medical aesthetics like Botox Cosmetic and CoolSculpting, but also spa...

Guardant Health study shows liquid biopsy picking up more mutations, delivering...

Published results of a liquid biopsy study in lung cancer patients could lead oncologists to prioritize blood-based genomic sequencing over traditional tissue testing. Redwood City,...

Lithuanian CDMO adding biologics capacity and more than 60 jobs

Biologics continue to be a growth area for pharma, and a Lithuanian contract manufacturer intends to get a bigger piece of the market with...

Virtual primary care startup 98point6 collaborates with health plan Banner|Aetna

98point6, a startup providing an on-demand, text-based primary care service, has teamed up with Banner|Aetna, the Arizona health plan owned by Banner Health and...

Consumer watchdog petitions FDA for black box warning on Amgen’s Prolia

The FDA has warned patients using Amgen’s osteoporosis drug Prolia that stopping treatment could lead to an increased risk of spinal fractures. Now, a...

Orderly Health is shifting its focus to ensuring provider data accuracy

Kevin Krauth grew up in a healthcare family — his father was a doctor and his mother was a nurse. Krauth ended up working in...

HIV drugmakers ViiV, Gilead top 2018 pharma reputation survey

Pharma’s reputation is holding steady. That’s according to the annual patient group opinion report from PatientView, which found that 41% thought the pharma industry reputation's...

Failure of once-promising Alzheimer’s drug reinforces doubts about amyloid beta

For nearly a decade, aducanumab played a starring role in Biogen’s late-stage pipeline. It had made its way into two Phase III trials thanks to...

Time to give up on biosims, experts say. Price regulations would...

The U.S. biosims market has been notoriously slow to generate meaningful savings or price reductions, and now some experts say it’s time to scrap...
0FansLike
65,684FollowersFollow
22,671SubscribersSubscribe

EDITOR PICKS